Tag: CorFlow

CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients

Financial by 0 comments

BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital, CorFlow’s initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate. “The improvement in […]

Continue Reading →

CorFlow Announces Positive Data from the MOCA I First in Human Study Presented at EuroPCR 2023

Coronary/Structural Heart by 0 comments

Novel CoFI device found to be safe and highly effective in detecting coronary microvascular obstruction (MVO) in the cathlab immediately after primary PCI PARIS–(BUSINESS WIRE)–CorFlow Therapeutics AG, a clinical-stage company that has developed the world’s first combined system for diagnostic assessment and therapy delivery to address coronary microvascular obstruction (MVO), […]

Continue Reading →

CorFlow Reports Late-Breaking Data from the “MOCA I” Clinical Trial

Coronary/Structural Heart by 0 comments

BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (“CorFlow”) announced today that Dr. Felice Gragnano, MD, Inselspital, Bern University Hospital, Bern, Switzerland, has presented interim clinical data from the MOCA I Phase 2 clinical trial during the PCR e-Course. The MOCA I study is a first-in-human (FIH) clinical trial to document the safety and feasibility of the CorFlow Controlled Flow […]

Continue Reading →

MCRA Assists CorFlow in Obtaining Breakthrough Device Designation

Coronary/Structural Heart by 0 comments

WASHINGTON, Dec. 3, 2019 /PRNewswire/ — MCRA, LLC, a leading medical device advisory firm and Clinical Research Organization (CRO) that integrates regulatory, clinical research, reimbursement, compliance and quality assurance, is pleased to announce its role in the successful granting of a Breakthrough Device Designation for the CorFlow Therapeutics AG Controlled Flow Infusion (CoFITM) […]

Continue Reading →

FDA grants “Breakthrough Device Designation” to CorFlow Therapeutics to expedite clinical development and regulatory review of its CoFI™ (COF-fee) System

Coronary/Structural Heart Regulatory by 0 comments

BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the FDA has designated the company’s CoFI (CorFlow Controlled Flow Infusion) System as a “Breakthrough Device” with a broad indication-for-use statement: “The CoFI™ System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a platform for controlled infusion of therapeutic agents […]

Continue Reading →

CorFlow Completes USD 9.7M in Seed Fundin

Financial by 0 comments

BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company has completed the 2nd close of its Seed+ financing round. To date, and since the CorFlow foundation in 2016, the company has raised a total of USD 9.7M (CHF 9.4M) in seed funding. The seed rounds have been funded by experienced private […]

Continue Reading →